TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Catheter Precision ( (VTAK) ) is now available.
On November 17, 2025, Catheter Precision, Inc. announced the termination of its At-Market-Offering Agreement with Ladenburg Thalmann & Co. Inc., effective November 24, 2025. The agreement allowed the company to sell shares of its common stock up to $4.3 million, of which approximately $4.0 million had been sold prior to termination. The company will not incur any penalties due to this termination.
The most recent analyst rating on (VTAK) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Catheter Precision stock, see the VTAK Stock Forecast page.
Spark’s Take on VTAK Stock
According to Spark, TipRanks’ AI Analyst, VTAK is a Underperform.
VTAK’s overall stock score is low due to significant financial challenges, including declining revenues and persistent losses. Technical analysis indicates bearish momentum, and the valuation is unattractive with a negative P/E ratio. These factors collectively suggest a high-risk investment.
To see Spark’s full report on VTAK stock, click here.
More about Catheter Precision
Average Trading Volume: 170,775
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.87M
Learn more about VTAK stock on TipRanks’ Stock Analysis page.